Cargando…
Short-term real-world outcomes following intravitreal brolucizumab for neovascular AMD: SHIFT study
BACKGROUND: Brolucizumab has recently been approved in Europe as a novel treatment for patients with neovascular age-related macular degeneration (nAMD). We report on early experiences with real-world outcomes of switch to brolucizumab therapy in previously anti-vascular endothelial growth factor (a...
Autores principales: | Bulirsch, Louisa Maria, Saßmannshausen, Marlene, Nadal, Jennifer, Liegl, Raffael, Thiele, Sarah, Holz, Frank G |
---|---|
Formato: | Online Artículo Texto |
Lenguaje: | English |
Publicado: |
BMJ Publishing Group
2022
|
Materias: | |
Acceso en línea: | https://www.ncbi.nlm.nih.gov/pmc/articles/PMC9411904/ https://www.ncbi.nlm.nih.gov/pubmed/33846161 http://dx.doi.org/10.1136/bjophthalmol-2020-318672 |
Ejemplares similares
-
Gains in the current understanding of managing neovascular AMD with brolucizumab
por: Bodaghi, Bahram, et al.
Publicado: (2023) -
Short-Term Morphofunctional Changes in Previously Treated Neovascular AMD Eyes Switched to Brolucizumab
por: Viggiano, Pasquale, et al.
Publicado: (2022) -
Early OCT Angiography Changes of Macular Neovascularization in Patients with Exudative AMD Treated with Brolucizumab in a Real-World Setting
por: Rübsam, Anne, et al.
Publicado: (2022) -
Brolucizumab and fluid in neovascular age-related macular degeneration (n-AMD)
por: Sharma, Ashish, et al.
Publicado: (2020) -
Manifestations of intraocular inflammation over time in patients on brolucizumab for neovascular AMD
por: Khoramnia, Ramin, et al.
Publicado: (2021)